ADMS Adamas Pharmaceuticals Inc.

5.27
-0.18  -3%
Previous Close 5.45
Open 5.13
Price To Book 7.42
Market Cap 146,810,216
Shares 27,857,726
Volume 266,222
Short Ratio
Av. Daily Volume 743,233
Stock charts supplied by TradingView

NewsSee all news

  1. Adamas Announces New Employment Inducement Grant

    EMERYVILLE, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted two new employees the option

  2. Adamas Provides Preliminary Fourth Quarter and Full Year 2019 GOCOVRI® Product Sales and Outlines Key Priorities for 2020

    -- Product sales expected to be approximately $16.3 million for fourth quarter 2019 and approximately $54.6 million for full year 2019 -- -- Total prescriptions of approximately 7,160 for fourth quarter 2019 and

  3. Adamas Announces Settlement of Patent Litigation with Sandoz Inc.

    EMERYVILLE, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people

  4. E-Scape Bio Appoints Anthony Rimac as Chief Financial Officer and Ann Kapoun, Ph.D., as SVP of R&D

    E-Scape Bio, Inc., a clinical stage, privately held biopharmaceutical company developing novel, precisely-targeted therapeutics for genetically-defined neurodegenerative diseases, today announced the appointment of Tony

  5. Adamas Announces Top-Line Results from INROADS Phase 3 Trial of ADS-5102 for Multiple Sclerosis Patients with Walking Impairment

    - INROADS study achieved its primary endpoint (proportion of responders with at least a 20% improvement from baseline to Week 12) - - Dose-response observed for both efficacy and safety - - Safety data consistent with

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Further development deferred - noted May 9, 2019.
ADS-4101
Partial onset seizures in patents with epilepsy
Phase 3 data met primary endpoint at one of two doses. Secondary endpoint in walking impairment not met. Second trial will not be initiated as a result of data - December 17, 2019.
GOCOVRI (amantadine)
Multiple sclerosis (MS)
Approved December, 24 2014.
Namzaric
Moderate to severe dementia of the Alzheimer's type.
Approval announced August 24, 2017.
ADS-5102
Levodopa-Induced Dyskinesia
Phase 3 open-label data released April 19, 2018.
GOCOVRI (amantadine)
Dyskinesia patients with Parkinson's disease

Latest News

  1. Adamas Announces New Employment Inducement Grant

    EMERYVILLE, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted two new employees the option

  2. Adamas Provides Preliminary Fourth Quarter and Full Year 2019 GOCOVRI® Product Sales and Outlines Key Priorities for 2020

    -- Product sales expected to be approximately $16.3 million for fourth quarter 2019 and approximately $54.6 million for full year 2019 -- -- Total prescriptions of approximately 7,160 for fourth quarter 2019 and

  3. Adamas Announces Settlement of Patent Litigation with Sandoz Inc.

    EMERYVILLE, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people

  4. E-Scape Bio Appoints Anthony Rimac as Chief Financial Officer and Ann Kapoun, Ph.D., as SVP of R&D

    E-Scape Bio, Inc., a clinical stage, privately held biopharmaceutical company developing novel, precisely-targeted therapeutics for genetically-defined neurodegenerative diseases, today announced the appointment of Tony

  5. Adamas Announces Top-Line Results from INROADS Phase 3 Trial of ADS-5102 for Multiple Sclerosis Patients with Walking Impairment

    - INROADS study achieved its primary endpoint (proportion of responders with at least a 20% improvement from baseline to Week 12) - - Dose-response observed for both efficacy and safety - - Safety data consistent with

  6. Glancy Prongay & Murray LLP Announces Investigation on Behalf of Adamas Pharmaceuticals, Inc. Investors

    Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company") (NASDAQ: ADMS) investors concerning the Company and its officers' possible violations of federal securities laws.

  7. INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Adamas Pharmaceuticals, Inc. Investors

    Law Offices of Howard G. Smith announces an investigation on behalf of Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company") (NASDAQ: ADMS) investors concerning the Company and its officers' possible violations of federal securities laws.

  8. Adamas Announces New Employment Inducement Grant

    EMERYVILLE, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted four new employees the option

  9. Adamas to Present at Upcoming Evercore ISI and Piper Jaffray Investor Conferences

    EMERYVILLE, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders,

  10. Adamas Announces New Employment Inducement Grant

    EMERYVILLE, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted three new employees the

  11. Adamas Reports Third Quarter 2019 Financial Results

    - Third quarter GOCOVRI® product sales of $13.9 million; total prescriptions grew to approximately 6,640 - Topline results from INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with

  12. Adamas to Announce Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019

    EMERYVILLE, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the company will report 2019 third quarter financial results on Thursday, November 7, 2019, after

  13. Adamas Announces New Employment Inducement Grant

    EMERYVILLE, Calif., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted five new employees the option

  14. Adamas to Present at Upcoming Cantor Fitzgerald Investor Conference

    EMERYVILLE, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders,

  15. Adamas Announces New Safety and Efficacy Data for GOCOVRI® in Parkinson's Disease Patients with Dyskinesia at the Movement Disorder Society 2019 International Congress

    EMERYVILLE, Calif., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS)

  16. Adamas Announces New Employment Inducement Grant

    EMERYVILLE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted its new Chief Executive

  17. Adamas Pharmaceuticals Appoints Neil McFarlane as Chief Executive Officer

    - Gregory Went, Ph.D., Founder, transitions to a strategic advisory role - David Mahoney, lead independent director, appointed to Chairman of the Board EMERYVILLE, Calif., Sept. 13, 2019 (GLOBE NEWSWIRE) --

  18. Adamas Announces New Employment Inducement Grant

    EMERYVILLE, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the compensation committee of the company's board of directors granted four new employees the